POMDOCTOR LIMITED: stock overview

POMNASDAQConsumer cyclical · Retail-Miscellaneous Retail

Price

$1.62

November 13, 2026

DCF calculator

What Ploutos Investor adds for POMDOCTOR

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
  • The debt we can read is far below what the company's own annual report says falls due over the coming years, so most of its borrowing is in figures we cannot read. We leave out the debt, net cash, enterprise value and the multiples built on them.

In short

POMDOCTOR had revenue of $57M in the fiscal year to December 31, 2025 and a net loss of $30M. Revenue grew by 14.5% a year on average over the last 2 years. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
–
58.08M shares
P/E
–
Revenue, fiscal year
$57M
+14.5% a year over 2 years
Net margin
-53.2%
2025: -32.7%, above 4% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+14.5% a year over 2 years

  • 202520-F
    Revenue$57M
  • 2024
    Revenue$47M
  • 2023
    Revenue$43M

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Sorry, we do not have enough data

for the “Valuation” group

Profitability

Gross margin 
13.1%
Operating margin 
-29.7%
Net margin 3-year median: -47.7%
-53.2%
ROIC 
–
ROE 
–

Growth

Revenue, yearly change 
+16.7%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
+14.5%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$1.4M
Total debt 
–
Net cash 
–
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+53.4%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 59).

Gross margin

13.1%

Above 9% of the 51 companies in its industry, and 13% of all.

Operating margin

-29.7%

Above 5% of the 65 companies in its industry, and 11% of all.

Net margin

-32.7%

Above 4% of the 66 companies in its industry, and 10% of all.

ROA

-121.7%

Above 2% of the 64 companies in its industry, and 1% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
POMDOCTOR Ltd
CIK
1877971
Exchange
NASDAQ
Industry (SIC)
5900 · Retail-Miscellaneous Retail
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
CNY
Shares
58.08M

Other companies: Consumer cyclical

The largest companies of the same sector, each with its own page.

The Consumer cyclical sectorAll companies

The full analysis

What do POMDOCTOR's filings show?

These are POMDOCTOR's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about POM

Didn't find what you were looking for?

Ask us
How much revenue does POM have?

POMDOCTOR had revenue of $57M in the fiscal year to December 31, 2025. Over the last 2 years it changed by +14.5% a year on average.

Does POM pay a dividend?

No. POMDOCTOR paid no regular dividend over the last 12 months.

Where do the figures come from?

From POMDOCTOR LIMITED's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.